Abstract
Like many other complex human disorders of unknown aetiology, autoimmune-mediated type 1 diabetes may ultimately be controlled via a therapeutic approach that combines multiple agents, each with differing modes of action. The numerous advantages of such a strategy include the ability to minimize toxicities and realize synergies to enhance and prolong efficacy. The recognition that combinations might offer far-reaching benefits, at a time when few single agents have yet proved themselves in well-powered trials, represents a significant challenge to our ability to conceive and implement rational treatment designs. As a first step in this process, the Immune Tolerance Network, in collaboration with the Juvenile Diabetes Research Foundation, convened a Type 1 Diabetes Combination Therapy Assessment Group, the recommendations of which are discussed in this Perspective paper.
Publication types
-
Guideline
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antigen Presentation / drug effects
-
Antigen Presentation / immunology
-
Autoantibodies / biosynthesis
-
Autoantibodies / immunology
-
Clinical Protocols / standards
-
Clinical Trials as Topic
-
Combined Modality Therapy
-
Diabetes Mellitus, Type 1 / drug therapy
-
Diabetes Mellitus, Type 1 / immunology
-
Diabetes Mellitus, Type 1 / therapy*
-
Drug Approval* / legislation & jurisprudence
-
Drug Design*
-
Drug Evaluation, Preclinical
-
Drug Therapy, Combination
-
Drugs, Investigational / therapeutic use
-
Humans
-
Hypoglycemic Agents / pharmacology
-
Hypoglycemic Agents / therapeutic use
-
Immunologic Factors / pharmacology
-
Immunologic Factors / therapeutic use
-
Immunosuppressive Agents / pharmacology
-
Immunosuppressive Agents / therapeutic use
-
Immunotherapy / methods*
-
Islets of Langerhans / drug effects
-
Islets of Langerhans / pathology
-
Lymphocyte Activation / drug effects
-
Lymphocyte Activation / immunology
-
Lymphocyte Subsets / drug effects
-
Lymphocyte Subsets / immunology
-
Mice
-
Mice, Inbred NOD
-
United States
-
United States Food and Drug Administration
Substances
-
Autoantibodies
-
Drugs, Investigational
-
Hypoglycemic Agents
-
Immunologic Factors
-
Immunosuppressive Agents